Date: 2015-10-20
Type of information: R&D agreement
Compound:
Company: Evotec (Germany) Beyond Batten Disease Foundation (USA - TX)
Therapeutic area: Rare diseases - Neurodegenerative diseases - Genetic diseases
Type agreement: R&D collaboration
Action mechanism:
Disease: juvenile Batten disease or juvenile neuronal ceroid lipofuscinosis
Details: * On October 20, 2015, Evotec announced an EVT Execute collaboration with Beyond Batten Disease Foundation (“BBDF”) aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. Under the terms of the agreement, Evotec will develop and use in vivo mechanistic and efficacy assays to assess the translational potential of fundamental and early drug discovery findings emerging from academic institutions in the United States and Europe. The goal of this programme is to leverage Evotec’s broad discovery expertise and experience to validate findings and to initiate their translation from bench to bedside. Evotec joins a dynamic, multidisciplinary pipeline of foundation-led activity designed to prioritise therapeutically promising findings while de-emphasising programmes that under-perform in the translational space.
Financial terms: The collaboration includes substantial research funding to Evotec and runs to the end of 2017, with an option to extend beyond this period. Further financial details were not disclosed.
Latest news:
